Update in Psoriasis: Optimizing Combination Topical Therapies to Improve Adherence and Patient Outcomes TEST 1. What is the National Psoriasis Foundation’s target response for psoriasis therapy? A. ≥50% improvement at 3 months from treatment initiation, progressing to ≥75% improvement at 6 months A. ≥75% improvement at 3 months and BSA <5% C. ≥75% improvement at 6 months and a BSA <3% D. BSA <1% at 3 months, maintained at subsequent evaluations every 6 months 2. How does the efficacy and safety of a fixed-dose combination of topical calcipotriene and betamethasone dipropionate (Cal/BD) compare with the use of each topical active ingredient as monotherapy in psoriasis? A. Higher efficacy and higher rate of side effects B. Higher efficacy and similar or lower rate of side effects C. Similar efficacy and lower rate of side effects D. Similar efficacy and similar rate of side effects 3. Roughly what proportion of patients with psoriasis achieved clear/almost clear with HP/TAZ lotion in a pooled analysis of two phase 3 studies? A. 25% B. 40% C. 60% D. 80% 4. Which of the following strategies is likely the most effective for improving a patient’s adherence to medication? A. Schedule a follow-up visit B. Involve family members when counseling patients C. Ask patients to keep a daily log D. Simplify the treatment schedule
